Abstract
Approximately 5.7 million people died from stroke in 2005 [1]. According to World Health Organization estimates, figures are predicted to increase to 23 million first-ever strokes, 77 million stroke survivors, 61 million disability adjusted life years (DALYs) and 7.8 million deaths in the next 20 years [2]. Heart disease and stroke are leading causes of DALYs lost and deaths worldwide [3]. Over 70 % of ischemic strokes are first events, which makes primary prevention immensely important. The treatments for acute ischemic stroke have emerged during the last decade and there is growing evidence of efficacy and importance of secondary prevention. We foresee that patients at high risk of vascular events could reduce their risk by 75 to 80 % through optimal prevention strategies including a combination of lifestyle changes and medical therapy [4]. In this review, we will focus on the aspects of antithrombotic treatment of ischemic stroke (IS) in the primary and secondary prevention.
Keywords: Stroke, cerebral infarction, antiplatelet medication, antithrombotics, anticoagulants, aspirin, warfarin, prevention
Current Drug Targets
Title: Antithrombotic Treatment in the Prevention of Ischemic Stroke
Volume: 8 Issue: 7
Author(s): Ufuk Emre, Kirsi Rantanen and Turgut Tatlisumak
Affiliation:
Keywords: Stroke, cerebral infarction, antiplatelet medication, antithrombotics, anticoagulants, aspirin, warfarin, prevention
Abstract: Approximately 5.7 million people died from stroke in 2005 [1]. According to World Health Organization estimates, figures are predicted to increase to 23 million first-ever strokes, 77 million stroke survivors, 61 million disability adjusted life years (DALYs) and 7.8 million deaths in the next 20 years [2]. Heart disease and stroke are leading causes of DALYs lost and deaths worldwide [3]. Over 70 % of ischemic strokes are first events, which makes primary prevention immensely important. The treatments for acute ischemic stroke have emerged during the last decade and there is growing evidence of efficacy and importance of secondary prevention. We foresee that patients at high risk of vascular events could reduce their risk by 75 to 80 % through optimal prevention strategies including a combination of lifestyle changes and medical therapy [4]. In this review, we will focus on the aspects of antithrombotic treatment of ischemic stroke (IS) in the primary and secondary prevention.
Export Options
About this article
Cite this article as:
Ufuk Emre , Kirsi Rantanen and Turgut Tatlisumak , Antithrombotic Treatment in the Prevention of Ischemic Stroke, Current Drug Targets 2007; 8 (7) . https://dx.doi.org/10.2174/138945007781077409
DOI https://dx.doi.org/10.2174/138945007781077409 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulating Mitophagy in Mitochondrial Disease
Current Medicinal Chemistry Tacrolimus Treatment in Myasthenia Gravis
Current Drug Therapy Atorvastatin and Diabetic Vascular Complications
Current Pharmaceutical Design Inflammatory Responses to Respiratory Syncytial Virus (RSV) Infection and the Development of Immunomodulatory Pharmacotherapeutics
Current Medicinal Chemistry Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk
Current Vascular Pharmacology Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme
Current Clinical Pharmacology Platelet Activation by Extracellular Matrix Proteins in Haemostasis and Thrombosis
Current Pharmaceutical Design Atherosclerosis - New Targets and Therapeutics
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design Editorial Nutritional Therapy in Metabolic Syndrome
Current Vascular Pharmacology Towards the Design of Social Media to Promote Physical Activity
Recent Advances in Communications and Networking Technology (Discontinued) Targeting the Arrhythmogenic Substrate in Atrial Fibrillation: Focus on Structural Remodeling
Current Drug Targets Repurposing Drugs for Cancer Prevention
Current Topics in Medicinal Chemistry Pharmacological Treatment of Obstructive Sleep Apnea
Current Pharmaceutical Design Is Combined Angiotensin-converting Enzyme Inhibition and Angiotensin Receptor Blockade Associated with Increased Risk of Cardiovascular Death in Hemodialysis Patients?
Current Hypertension Reviews Short-term RR-Interval Power Spectral Analysis as a New Tool to Stratify the Risk of Sudden Death in Various Cardiovascular Conditions
Vascular Disease Prevention (Discontinued) Protective Effect of Annurca Apple Extract Against Oxidative Damage in Human Erythrocytes
Current Nutrition & Food Science Sleep Apnea and Coronary Heart Disease: From Dusk Till Dawn and Further
Current Respiratory Medicine Reviews Epidemiological Characteristics of 64 Covid-19 Patients in Errachidia Province (Darâa-Tafilalet region), Morocco: A Retrospective Analysis
Reviews on Recent Clinical Trials